EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study

Spencer Frost, Chetan Ambastha iD, Devin Patel, Andrew Roney, Alexandra Greb, Maricela Rangel-Garcia, Jenny S Sauk, Christopher Chang, Sunhee Park iD, Alyssa Parian iD, Andrew Suchan, Eric Moughames und 9 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf170 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Spencer Frost und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors, Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It has been theorized that age related immunosenescence reduces the risk of developing anti-drug antibodies (ADAs). This has significant implications regarding choice of therapy and need for routine drug monitoring in this group. We investigated the incidence of ADAs in older adults compared to younger adults with inflammatory bowel disease (IBD).

Methods

We conducted a multicenter retrospective cohort study including all older adults (ages ≥60 years) with IBD treated with a tumor necrosis factor inhibitors (TNFi); adults ages 18-59 years old were included in a 4:1 ratio. Kaplan-Meier and Cox regression methods compared longitudinal risk of ADA development between groups. Multivariable models evaluated the association of potential risk factors with ADA development.

Results

182 (19.7%) older adults and 738 (80.2%) younger adults were included in the study. The risk of ADAs was higher in older adults compared to younger adults (adjusted hazard ratio [aHR] 2.20; 95% confidence interval [CI] 1.44-3.36). Proactive therapeutic drug monitoring (TDM) was inversely associated with ADA development (aHR 0.36; 95% CI 0.25-0.52).

Conclusion

Older adults are more likely to develop ADAs against TNFi compared to younger adults. Proactive TDM may be considered in this population for early identification of ADAs and subtherapeutic trough levels, enabling timely dose escalation or treatment modification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntibodiesGastrointestinal AgentsHumansRetrospective StudiesMaleAdultMiddle AgedFemaleIncidenceYoung AdultAgedAdolescentDrug MonitoringAge FactorsRisk FactorsFollow-Up Studies

Substanzen

Tumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntibodiesGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States.
  • Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
  • Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
  • Division of Gastroenterology, University of California Irvine, Irvine, CA, United States.
  • Department of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, United States.
  • Department of Medicine, Johns Hopkins University, Baltimore, MD, United States.

ORCID-Profile: Chetan Ambastha, Sunhee Park, Alyssa Parian, Kian Keyashian

Zitieren

APA

Frost, S., Ambastha, C., Patel, D., Roney, A., Greb, A., Rangel-Garcia, M., Sauk, J. S., Chang, C., Park, S., Parian, A., Suchan, A., Moughames, E., Krishna, M., Chowdhury, R., Sharma, S., Maas, L., Ho, A., Lazarev, M., Limketkai, B. N., …, & Keyashian, K. (2025). Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf170

Vancouver

Frost S, Ambastha C, Patel D, Roney A, Greb A, Rangel-Garcia M, et al. Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf170

BibTeX
@article{Frost2025,
  author = {Frost, Spencer and Ambastha, Chetan and Patel, Devin and Roney, Andrew and Greb, Alexandra and Rangel-Garcia, Maricela and Sauk, Jenny S and Chang, Christopher and Park, Sunhee and Parian, Alyssa and Suchan, Andrew and Moughames, Eric and Krishna, Mahesh and Chowdhury, Reezwana and Sharma, Sowmya and Maas, Laura and Ho, Andrew and Lazarev, Mark and Limketkai, Berkeley N and Limsui, David and Keyashian, Kian},
  title = {Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf170}
}
Kostenlos starten →